The value of recurrence or metastasis of 18F-FDG PET/CT and serumCEA in patients with advanced gastric cancer after neoadjuvant chemotherapy combined with surgical treatment
10.3969/j.issn.1673-4130.2017.17.018
- VernacularTitle:18F-FDG PET/CT与血清CEA对进展期胃癌新辅助化疗联合手术治疗后转移或复发监测价值
- Author:
Fengkun ZHANG
;
Weina ZHOU
;
Guojian ZHANG
;
Jun WU
- Keywords:
advanced gastric cancer;
18F-FDG PET/CT;
carcinoembryonic antigen;
recurrence;
metastasis
- From:
International Journal of Laboratory Medicine
2017;38(17):2383-2385
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the value of 18F-FDG PET/CT and serum CEA in patients with advanced gastric cancer after neoadjuvant chemotherapy combined with surgical treatment.Methods 96 cases of patients with advanced gastric cancer who underwent neoadjuvant chemotherapy combined with surgery as the research object,after more than 2 years of follow-up,PET/CT imaging and serum CEA levels were detected,and the diagnostic value of recurrence or metastasis of the two groups were evaluated and analyzed.Results Of the 96 patients enrolled in the study,there were 47 cases of recurrence and metastasis,PET/CT combined with CEA for recurrence or metastasis positive diagnosis rate and negative diagnosis rate was significantly higher than that of pure PET/CT and serum CEA,the difference was statistically significant(P<0.05).The sensitivity,specificity and accuracy of PET/CT combined with CEA in the diagnosis of recurrence or metastasis were higher than that of PET/CT and serum CEA,the difference was statistically significant(P<0.05).Conclusion The combined monitoring of 18F-FDG PET/CT imaging and serum CEA level in patients with advanced gastric cancer after neoadjuvant chemotherapy combined with surgical treatment is helpful to improve the diagnosis of metastasis or recurrence.
